MissionIR Articles
-
MissionIRNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) XPro1595 Highlighted During Press Conference at the Society for Neuroscience 49th Annual Meeting
INmune Bio (NASDAQ: INMB) on Monday announced that Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine, presented data…
-
MissionIRNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) Lead Compound XPro1595 Data to be Presented at the Society for Neuroscience’s Annual Meeting
INmune Bio, Inc. (NASDAQ: INMB) today announced a poster presentation related to its program in Alzheimer’s disease at the upcoming Society for Neuroscience (“SfN”) 49th Annual Meeting to be held at McCormick Place in Chicago…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Second Annual Advances in Immuno-Oncology USA Congress and World Immunotherapy Congress
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its Co-Founder and CEO RJ Tesi, M.D., will present at…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO Discusses Company Achievements in Interview; Director of Neuroscience to Present at World Immunotherapy Congress
RJ Tesi, M.D., co-founder and CEO of clinical-stage immunology company INmune Bio (NASDAQ: INMB), was recently featured in an interview with multimedia financial reporter Jason Lin. Among other highlights, Dr. Tesi discusses recent company accomplishments…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 AAIC Satellite Symposium
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its plans to present at the upcoming Alzheimer’s Association International…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Executives to Speak, Showcase Innate Compounds at Two Upcoming Events
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder and CEO, and Mark Lowdell, Ph.D.,…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Covering DN-TNFa Platform Technology for Treating Cancer
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its receipt of United States Patent and Trademark Office (“USPTO”) formal…
-
MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Reports Positive Q2 2019 Financial Results
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, recently reported financial results for the second quarter ended June 30, 2019 (http://ibn.fm/shHin). An…
-
MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03
INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ Tesi recently reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients during a presentation at Cambridge Healthtech Institute’s 7th Annual…
-
INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategic Appointment
The immunology company released its financial results for the second quarter of 2019 and also delivered an update on its clinical trials The phase I trial of INmune Bio’s cancer treatment INB03 has delivered promising…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides Shareholder Update
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its financial results for the second quarter ended June 30, 2019…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Names Biotechnology Executive as New Board Member
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Edgardo “Ed” Baracchini, Ph.D., has joined its board of directors. Per…
-
INmune Bio Inc. (NASDAQ: INMB) Planning Phase II Trial of INB03 as Part of Combination Immunotherapy for Cancer Patients
INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Reports Positive Preliminary Data from Phase I Clinical Trial of INB03
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s Seventh…
-
INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of International Drug Discovery Science & Technology
INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Co-Founder and CEO to Present at Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Co-Founder and CEO RJ Tesi, M.D. will present…
-
Research Highlights Virtues of INmune Bio Inc.’s (NASDAQ: INMB) Strategy in Fighting Cancer with Body’s Own Natural Cells
California-based INmune Bio is developing therapies to battle cancers and Alzheimer’s disease by more effectively engaging the body’s own natural defenses Research published in a peer-reviewed scientific journal shows a mechanism by which scientists can…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at 17th Annual Congress of International Drug Discovery Science & Technology 2019
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Director of Neuroscience, C.J. Barnum, and Co-Founder and CEO,…
-
MissionIRNewsBreaks – INmune Bio Inc.’s (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflammation to Treat Alzheimer’s Disease
INmune Bio (NASDAQ: INMB) is an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, such as Alzheimer’s disease (“AD”). A recent article discussing the company reads, “An…
-
TNF Inhibitors Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595 May Reduce the Risk of Alzheimer’s Development, Report Suggests
Research indicates that anti-inflammatory medications have the power to prevent the onset and control the symptoms of Alzheimer’s disease The link between inflammatory processes and Alzheimer’s has long been established; companies like INmune Bio are…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Duos Technologies Group, Inc. (NASDAQ: DUOT) Prices $65M Public Offering to Advance Edge Data Center Expansion
- MissionIRNewsBreaks – ClearThink 1 Acquisition Corp. (NASDAQ: CTAAU) Closes $125M Initial Public Offering
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Reports Surge in Institutional Ownership as Platform Expansion Accelerates
- Forward Industries Inc. (NASDAQ: FWDI) Executes the Company’s Solana Treasury Strategy to Build on a Successful 2026 Fiscal Q1
- MissionIRNewsBreaks – Olenox Industries (NASDAQ: OLOX) Launches 2026 Drilling Program, Targets 1,000 BOE per Day by Year-End